(Health Korea News / Soon-ho Lee) Chong Kun Dang appears to be interested in developing new indications for its self-developed natural ingredient gastritis treatment ‘Gitec (ingredient name: dried broiler extract (16~26 → 1))’. Although research is still in its early stages, non-clinical trials have shown positive results. As this is a product that has not yet been released, attention is being paid to whether the company will begin work on expanding early indications in earnest.
Professor Kim Min-jae’s research team from the Department of Internal Medicine at Gangnam Severance Hospital recently published an article in MEDICINA, an SCI(E)-level international academic journal, titled ‘The effects of CKD-495, upacidin, and their index components on changes in permeability in an animal model of intestinal obstruction after surgery ( A research paper titled ‘The Effect of CKD-495, Eupacidin, and Their Marker Compounds on Altered Permeability in a Postoperative Ileus Animal Model’ was published.
‘CKD-495’ is the name of the development project of ‘G-Tech’. This study was conducted to predict the drug repositioning effect of ‘Gitec’ and to provide experimental evidence for this. This is a non-clinical test that evaluated the therapeutic effect of ‘Gitec’ using guinea pigs that induced intestinal obstruction after surgery.
Postoperative ileus is a common and serious complication caused by delayed passage of the gastrointestinal tract after surgery. It can occur after any type of surgery, but is especially associated with abdominal surgery. Previous animal model studies have shown that increased intestinal inflammation and permeability are key causes of postoperative ileus.
Accordingly, the research team used ‘Gitec’, which has an anti-inflammatory effect, to evaluate its potential to reduce intestinal permeability in guinea pigs that induced intestinal obstruction after surgery.
In the test, not only ‘Gitec’, but also Chong Kun Dang’s other representative herbal medicine ingredient, ‘Eupasidin (ingredient name: Aeup isopropanol soft extract (20→1))’, and cinnamic acid (Gitec) and eupatilin, which are indicator ingredients of these two products, were used together.
As both ‘Gitec’ and ‘Upacidin’ exert anti-inflammatory effects by regulating NF-κB signaling and reducing the production of inflammatory cytokines, it is believed that they can potentially improve the increase in intestinal permeability caused by intestinal obstruction after surgery. It’s from.
As a result of the study, the group taking ‘Gitec’, ‘Upasidin’, cinnamic acid, and upatilin orally had significantly reduced intestinal permeability compared to the test group that did not take any drugs, and depending on the dose, intestinal obstruction did not occur after surgery. Intestinal permeability was lower than that of the normal control group.
The degree of intestinal inflammation was measured through increased white blood cell counts, and the white blood cell count was found to be lower in all drug-taking groups compared to the non-drug group. Depending on the dose, test groups were also confirmed to have white blood cell counts similar to those of the normal control group.
The researchers said, “’Gitek’, along with its main active ingredient, cinnamic acid, effectively suppressed the increase in intestinal permeability and inflammation caused by postoperative intestinal obstruction at all doses tested in animal models,” adding, “Similar mean values observed between ‘Gitec’ and cinnamic acid treatment groups. “This suggests that cinnamic acid contributes most to this protective effect.”
In particular, recent research has shown that cinnamic acid can regulate intestinal microflora and short-chain fatty acids, which are closely related to intestinal inflammation and permeability, the researchers explained.
The researchers continued, “Eupatilin and ‘upacidin’ were also effective in preventing increased intestinal permeability and inflammation in an animal model of ileus after surgery,” adding, “All four agents used in this study were effective when administered before surgery and after surgery. “It has the potential to suppress the development of intestinal obstruction,” he emphasized.
‘Gitek’ is a natural medicine that was the first to prove its efficacy against gastritis by applying a new extraction method developed by Chong Kun Dang to broilers, a medicinal material made from the dried stem bark of the camphor tree and the bark of the chinensis tree.
Since 2013, Chong Kun Dang has been exploring various herbal medicines for materials and extraction methods that have the potential to differentiate them from existing drugs. After confirming the efficacy of treating gastritis in broiler chickens, Chong Kun Dang developed ‘Gitek’ and obtained product approval from the Ministry of Food and Drug Safety in July 2022. . However, the launch is being delayed as drug price negotiations with the government have not yet been completed.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
